PI-103

PI-103は、強力な、細胞透過性、ATP競争的クラスI PI3K阻害剤で、DNA-PK、 p110α、 mTORC1、 PI3-KC2β、 p110δ、 mTORC2、 p110β、p110γ に作用すると、IC50 がそれぞれ 2 nM、 8 nM、 20 nM、26 nM、 48 nM、 83 nM、 88 nM 、150 nMになる。

価格 在庫  
USD 168 あり
USD 185 あり
USD 340 あり
USD 466 あり

PI-103 化学構造
分子量: 348.36

高品質保証

カスタマーフィードバック(4)

Quality Control & MSDS

製品説明

  • Compare PI3K Inhibitors
    PI3K製品生物活性の比較
  • 研究分野
  • PI-103のメカニズム

製品の説明

生物活性

製品説明 PI-103は、強力な、細胞透過性、ATP競争的クラスI PI3K阻害剤で、DNA-PK、 p110α、 mTORC1、 PI3-KC2β、 p110δ、 mTORC2、 p110β、p110γ に作用すると、IC50 がそれぞれ 2 nM、 8 nM、 20 nM、26 nM、 48 nM、 83 nM、 88 nM 、150 nMになる。
ターゲット p110α p110β p110δ p110γ mTOR DNA-PK
IC50 2 nM 3 nM 3 nM 15 nM 30 nM 23 nM [3]
In vitro試験 PI-103 potently inhibits both the rapamycin-sensitive (mTORC1) and rapamycin-insensitive (mTORC2) complexes of the protein kinase mTOR. [1] PI-103 inhibits constitutive and growth factor-induced PI3K/Akt, as well as mTORC1 activation. [2] In blast cells, PI-103 inhibits leukemic proliferation, the clonogenicity of leukemic progenitors and induces mitochondrial apoptosis, especially in the compartment containing leukemic stem cells. PI-103 inhibits p110α >200-fold more potently than p110β. PI-103 also potently blocks production of PI(3,4)P2 and PIP3 in adipocytes and PIP3 in myotubes. [2] PI-103 inhibits phosphorylation of Akt with an IC95 100-fold lower than that for LY294002. Strikingly, PI-103 completely protects animals from insulin-stimulated decline in blood glucose. PI-103 has additive proapoptotic effects with etoposide in blast cells and in immature leukemic cells. [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
SK-N-BE NGHUTY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7kNE05KM7:TR?= NFLIc|YzPC92OD:3NkBp NYrNfWVzcW6mdXPld{B1cW2nLTDhcoQh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgbY5pcWKrdHnvckBwdiCQQjDj[YxtKGe{b4f0bC=> MXWyOlIzPDZ6MR?=
SH-SY5Y MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWqwMVgh|ryP NWjReXVmOjRxNEivO|IhcA>? NXHKdYdrcW6mdXPld{B1cW2nLTDhcoQh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgbY5pcWKrdHnvckBwdiCQQjDj[YxtKGe{b4f0bC=> NIfsPFAzPjJ{NE[4NS=>
SH-SY5Y  NYn5ZlRlSXCxcITvd4l{KEG|c3H5 NEjLT40yKM7:TR?= M2L4bFAvPS1{NDDo MX\z[Y5{cXSrenXzJI5mfXKxYnzhd5RwdWFiY3XscJMhfG9iZH;4c5J2[mmlaX6tbY5lfWOnZDDhdI9xfG:|aYO= M1ztdVI3OjJ2Nkix
G 35 SC M2Pxb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkL4NE4xPS1{MDFOwG0> MViyOE84OiCq NHuzS|dFVVOR M{DIR4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51dHl? M2jHS|I3OTJzMkWx
G 38 SC M{n1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILyXW4xNjB3LUKwJO69VQ>? MkfWNlQwPzJiaB?= MlK3SG1UVw>? NVv4bIFrcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnSueR?= NWe4cW1TOjZzMkGyOVE>
G 40 SC M{XKfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfkeo9nOC5yNT2yNEDPxE1? MkLwNlQwPzJiaB?= MlvhSG1UVw>? M2\QbIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51dHl? NW[zcm0{OjZzMkGyOVE>
G 35 DC M{nGe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LsWlAvODVvMkCg{txO NFX1TGIzPC95MjDo MnLHSG1UVw>? MknzbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBidmRidHnt[UBl\XCnbnTlcpRtgQ>? M4n4SVI3OTJzMkWx
G 38 DC NGHYXYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvrSoYxNjB3LUKwJO69VQ>? MnLwNlQwPzJiaB?= MV\EUXNQ NHHRPVRqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfGy7 MWiyOlEzOTJ3MR?=
G 40 DC Ml\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvT[HMxNjB3LUKwJO69VQ>? NVvxV2F2OjRxN{KgbC=> NEDGR5JFVVOR MYrpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueIx6 MXuyOlEzOTJ3MR?=
RD MYrBdI9xfG:|aYOgRZN{[Xl? NWfGZ|RxOS9zLkWvNkDPxE1? MX23NkBp NV;VNYNDcW6mdXPld{BieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDDHRW5VPjF? MYCyOVc1QTN5OB?=
TE381.T MX7BdI9xfG:|aYOgRZN{[Xl? NYXSdJlPOS9zLkWvNkDPxE1? MV23NkBp NUHPT4VocW6mdXPld{BieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDDHRW5VPjF? MkHqNlU4PDl|N{i=
RMS13 M2\oSmFxd3C2b4Ppd{BCe3OjeR?= NWS3ZXR{OS9zLkWvNkDPxE1? NIPkdo04OiCq MVTpcoR2[2W|IHHwc5B1d3OrczDjc41jcW6nZDD3bZRpKEeDTmS2NS=> NHT3PGMzPTd2OUO3PC=>
RH30  M3;uPGFxd3C2b4Ppd{BCe3OjeR?= M2[xblEwOS53L{Kg{txO MXS3NkBp MYrpcoR2[2W|IHHwc5B1d3OrczDjc41jcW6nZDD3bZRpKEeDTmS2NS=> MU[yOVc1QTN5OB?=
VJ NXv1SHZZSXCxcITvd4l{KEG|c3H5 NX7rU5NCOS9zLkWvNkDPxE1? NHHKTJU4OiCq NW\HXog3cW6mdXPld{BieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDDHRW5VPjF? M2[wcFI2PzR7M{e4
HS578T MmPYR4VtdCCYaXHibYxqfHliQYPzZZk> MY[wMVMh|ryP M1zOOFczKGh? MmjybY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NHjZPYgzPTd{MUSxPS=>
BT549 NITMSWpE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MofhNE0{KM7:TR?= NVr0R5FCPzJiaB?= M2P2bYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NXrrcoN3OjV5MkG0NVk>
MDA-MB-231 MkDLR4VtdCCYaXHibYxqfHliQYPzZZk> NVrYZ5VIOC1|IN88US=> M13aeFczKGh? NFy1fGxqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NUD6[mpkOjV5MkG0NVk>
MDA-MB-468 NVvRdolUS2WubDDWbYFjcWyrdImgRZN{[Xl? NEXXUlgxNTNizszN MmfRO|IhcA>? NXLGeVNlcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= MX:yOVczOTRzOR?=
MDA-MB-436 MnfHR4VtdCCYaXHibYxqfHliQYPzZZk> M2\INFAuOyEQvF2= MnfpO|IhcA>? M37zS4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NVHWW2ZzOjV5MkG0NVk>
SUM149PT MWfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M2PXb|AuOyEQvF2= MXq3NkBp NHjKR2dqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NGjUSm4zPTd{MUSxPS=>
MDA-MB-468 MlHzSpVv[3Srb36gRZN{[Xl? MVywMlAyNTFyIN88US=> NHXPXFkzPCCq MknK[I94dnKnZ4XsZZRmeyC2aHWgcIV3\Wy|IH;mJO6zNVS{Q2CxMEBkNU27YzDhcoQh[3mlbHnuJGUheHKxdHXpcpPDqA>? NYO4fXo2OjV5MkG0NVk>
MDA-MB-231 NEHNfmdHfW6ldHnvckBCe3OjeR?= NIHyRWIxNjBzLUGwJO69VQ>? MoXFNlQhcA>? M4\FcIRwf26{ZXf1cIF1\XNidHjlJIxmfmWuczDv[kDPui2WclPQNUwh[y2PeXOgZY5lKGO7Y3zpckBGKHC{b4TlbY5{yqB? MoHLNlU4OjF2MUm=
HS578T M1e5dWZ2dmO2aX;uJGF{e2G7 MYSwMlAyNTFyIN88US=> NVLjU3M1OjRiaB?= MX7kc5dvemWpdXzheIV{KHSqZTDs[ZZmdHNib3[g{tIuXHKFUEGsJIMuVXmlIHHu[EBkgWOuaX6gSUBxem:2ZXnud:Kh NYLkVpNnOjV5MkG0NVk>
SW872 MlnnSpVv[3Srb36gRZN{[Xl? MXewMlAyNTBwNTFOwG0> M1fzUFI1KGh? MVXy[YR2[2W|IFHLWEBxcG:|cHjvdplt[XSrb36gLJBCU1RrIHHu[EA1TUKSMTDwbI9{eGixconsZZRqd25iKIC0SWJROSliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XMEoB?= MkfDNlQ3QTV4M{K=
SW982 NV3BbplkTnWwY4Tpc44hSXO|YYm= NGLmOFUxNjBzLUCuOUDPxE1? MVKyOEBp M{XNW5Jm\HWlZYOgRWtVKHCqb4PwbI9zgWyjdHnvckApeEGNVDmgZY5lKDSHQmCxJJBpd3OyaH;yfYxifGmxbjCodFRGSlBzKTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nctMg MonONlQ3QTV4M{K=
SW872 NVvNN497SXCxcITvd4l{KEG|c3H5 NHHjXYIxNjBzLUCuOUDPxE1? MYC0PEBp NWe4UVgzcW6mdXPld{BieG:ydH;zbZMh\G:|ZTDk[ZBmdmSnboTsfS=> NEO3dJgzPDZ7NU[zNi=>
SW982 NEXsV2RCeG:ydH;zbZMhSXO|YYm= NH;NWoYxNjBzLUCuOUDPxE1? NEDQZms1QCCq NUnkRpAxcW6mdXPld{BieG:ydH;zbZMh\G:|ZTDk[ZBmdmSnboTsfS=> MXKyOFY6PTZ|Mh?=
AGS HG Mm\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIThXmtKSzVyPUCuOlghyrFiMD6wN|Eh|ryP NFfPVJgzPDV7N{S3PC=>
AGS LG MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\jemlEPTB;MD6wOUDDuSByLkCwNUDPxE1? Ml:5NlQ2QTd2N{i=
HGC27 HG MmOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTBwM{igxtEhOC5yMkKg{txO NFrxb3UzPDV7N{S3PC=>
HGC27 LG MmLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPzWndKSzVyPUCuNFIhyrFiMD6wNFQh|ryP Mn3NNlQ2QTd2N{i=
MKN45 HG M{[weWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\qdYlvUUN3ME2xMlAyKMLzIECuNFUyKM7:TR?= M3\VPVI1PTl5NEe4
MKN45 LG NGj3PYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLhTZdMUUN3ME2wMlg4KMLzIECuNFMxKM7:TR?= M4\MTlI1PTl5NEe4
NUGC4 HG NFu2dlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTF2LkCgxtEhOy57MUOg{txO NXPWb|Z4OjR3OUe0O|g>
NUGC4 LG Mkj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjyV|dlUUN3ME2xOE4xKMLzIEWuN|IyKM7:TR?= NGXxdlMzPDV7N{S3PC=>
A549 MYPGeY5kfGmxbjDBd5NigQ>? M4TXOFAvOjVxMD61M|Eh|ryP MkS4NlQhcA>? NF\KV5VqdmirYnn0d{BCc3RicHjvd5Bpd3K7bHH0bY9vKHOuaXfoeIx6 MmrvNlQ{PTF2MkW=
H460 M3\HWWZ2dmO2aX;uJGF{e2G7 MoLYNE4zPS9yLkWvNUDPxE1? MnvTNlQhcA>? NF;lfmNqdmirYnn0d{BCc3RicHjvd5Bpd3K7bHH0bY9vKHOuaXfoeIx6 NUDzWJdKOjR|NUG0NlU>
H661 NVy0XmVSTnWwY4Tpc44hSXO|YYm= NVvuUIM{OC5{NT:wMlUwOSEQvF2= MkTjNlQhcA>? NXHYbWY1cW6qaXLpeJMhSWu2IIDoc5NxcG:{eXzheIlwdiC|aXfubYZq[2GwdHz5 NETxVJEzPDN3MUSyOS=>
SAS NGPBfYZHfW6ldHnvckBCe3OjeR?= MVWwMlI2NzBwNT:xJO69VQ>? NFjqcW4zPCCq NEfPXGxqdmirYnn0d{BCc3RicHjvd5Bpd3K7bHH0bY9vKHOrZ37p[olk[W62bIm= M{f1S|I1OzVzNEK1
UT5 NF;jbVFHfW6ldHnvckBCe3OjeR?= NILWfWUxNjJ3L{CuOU8yKM7:TR?= MUSyOEBp NFzBNHlqdmirYnn0d{BCc3RicHjvd5Bpd3K7bHH0bY9vKHOrZ37p[olk[W62bIm= MVOyOFM2OTR{NR?=
FaDu NFThcnhHfW6ldHnvckBCe3OjeR?= MkXENE4zPS9yLkWvNUDPxE1? MWKyOEBp MmTGbY5pcWKrdIOgRYt1KHCqb4PwbI9zgWyjdHnvckB{cWewaX\pZ4FvfGy7 NUTkSYk4OjR|NUG0NlU>
RD MVrBdI9xfG:|aYOgRZN{[Xl? M4XqT|EwOS53L{Kg{txO MUK3NkBp NXKyWGtRTE2VTx?= M1[3WYlv\HWlZYOgZ4F{eGG|ZT3k[ZBmdmSnboSgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhiVV:xNlY> NXPOOZl1OjN4OES5NlU>
TE671 NWHhOZA2SXCxcITvd4l{KEG|c3H5 NFvDOYUyNzFwNT:yJO69VQ>? MXi3NkBp M1;JWGROW09? MojUbY5lfWOnczDjZZNx[XOnLXTldIVv\GWwdDDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCCXT{GyOi=> NIDsOIkzOzZ6NEmyOS=>
RH30  NH71TnVCeG:ydH;zbZMhSXO|YYm= MVKxM|EvPS9{IN88US=> NHjL[2o4OiCq Ml\SSG1UVw>? NEfyO4tqdmS3Y3XzJINie3Cjc3Wt[IVx\W6mZX70JIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIGXPNVI3 NHjsSIkzOzZ6NEmyOS=>
RMS13 NXHicVliSXCxcITvd4l{KEG|c3H5 M3vmTFEwOS53L{Kg{txO M4Xp[VczKGh? NVrXZ|lITE2VTx?= NU\NfIxXcW6mdXPld{Bk[XOyYYPlMYRmeGWwZHXueEBieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDDVU|EzPg>? M4\RSlI{Pjh2OUK1
SUM149PT MoHNR4VtdCCYaXHibYxqfHliQYPzZZk> MViwMlMh|ryP Mnv1O|IhcA>? MXzlcohidmOnczDjfZRwfG:6aXOg[YZn\WO2czDv[kBRUTONL1HLWEBx[XSqd3H5JIlvcGmkaYTvdpM> NFLBUm0zOzZyMUC3OC=>
MDA-MB-468 MUjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NFnYWJIxNjNizszN MmjZO|IhcA>? NWDQRmpJ\W6qYX7j[ZMh[3m2b4TvfIlkKGWoZnXjeJMhd2ZiUFmzT{9CU1RicHH0bJdigSCrbnjpZol1d3K| MUOyN|YxOTB5NB?=
MDA-MB-231 NHztNlVE\WyuIG\pZYJqdGm2eTDBd5NigQ>? Mn\aNE4{KM7:TR?= NY\DWHc1PzJiaB?= MYflcohidmOnczDjfZRwfG:6aXOg[YZn\WO2czDv[kBRUTONL1HLWEBx[XSqd3H5JIlvcGmkaYTvdpM> MlzINlM3ODFyN{S=
SY5Y MmftSpVv[3Srb36gRZN{[Xl? NGHzW2oyNjVxMj61M|Uh|ryP MXyyOEBp M2rXOYlv\HWlZYOgS|HDqGOnbHytZ5lkdGViYYLy[ZN1KGGwZDDhdI9xfG:|aYO= NF;2S|AzOzN5OEO0NS=>
SKNBE(2c) Mk\QSpVv[3Srb36gRZN{[Xl? NVnmZ|M6OS53L{KuOU82KM7:TR?= MljINlQhcA>? MkTKbY5lfWOnczDHNeKh[2WubD3jfYNt\SCjcoLld5Qh[W6mIHHwc5B1d3Orcx?= M3XvfFI{Ozd6M{Sx
RD MVzBdI9xfG:|aYOgRZN{[Xl? Mnr4N{DDvU1? NHXnTnEyOiCq Mm\USG1UVw>? NHSxdGh{\W6|aYTpfoV{KFKGIHPlcIx{KHSxIFTPXE1qdmS3Y3XkJIFxd3C2b4Ppdy=> NX\4SFhKOjN|MEC4NFk>
TP5014 Mn;lRZBweHSxc3nzJGF{e2G7 NFXlPXY{KML3TR?= M2ixUFEzKGh? NXvGeGp5TE2VTx?= MYHz[Y5{cXSrenXzJHJFKGOnbHzzJJRwKESRWD3pcoR2[2WmIHHwc5B1d3Orcx?= Ml\ONlM{ODB6MEm=
HT1080 MXPBdI9xfG:|aYOgRZN{[Xl? NHXrN5U{KML3TR?= MlvWNVIhcA>? NUfQT3VMTE2VTx?= MkfEd4Vve2m2aYrld{BTTCClZXzsd{B1dyCGT2itbY5lfWOnZDDhdI9xfG:|aYO= NX3LfohHOjN|MEC4NFk>
A549 MnvJSpVv[3Srb36gRZN{[Xl? MmW2NE0{NjNizszN NVXmZoNiPzJiaB?= MlHUbY5lfWOnczDjc41xdGW2ZTDkc5dvemWpdXzheIlwdiCxZjDwRWtV NVP5XGNvOjN{NUm1PVE>
HCC827 MXzGeY5kfGmxbjDBd5NigQ>? M33zOVAuOy5|IN88US=> Mm\RO|IhcA>? NFnidYRqdmS3Y3XzJINwdXCuZYTlJIRwf26{ZXf1cIF1cW:wIH;mJJBCU1R? M2O3ZlI{OjV7NUmx
H3122 MVXGeY5kfGmxbjDBd5NigQ>? M1LGfFAuOy5|IN88US=> NHPqTIQ4OiCq NUjTdW55cW6mdXPld{Bkd22ybHX0[UBld3ewcnXneYxifGmxbjDv[kBxSUuW NFfJZZYzOzJ3OUW5NS=>
TALL-1 NXSweI4yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWr3Rm17OeLCid88US=> NF[5XY04KGR? NHLTUWtl\WO{ZXHz[ZMhfGinIHPlcIwhdnWvYnXyJJNq\26rZnnjZY51dHl? MofTNlMxOzh{N{O=
HPB-ALL M2T3dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXPVnYy6oDLzszN MoTIO{Bl NIGw[nVl\WO{ZXHz[ZMhfGinIHPlcIwhdnWvYnXyJJNq\26rZnnjZY51dHl? NWHDOY82OjNyM{iyO|M>
DND41 MkPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;GPVHjiIoQvF2= NXzVXHJyPyCm NUX1O2xx\GWlcnXhd4V{KHSqZTDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7 NFGw[nMzOzB|OEK3Ny=>
SUP-T1 M1[1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2frbFHjiIoQvF2= NWnq[4pLPyCm MoPw[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 MVKyN|A{QDJ5Mx?=
PEER NWjJU4Y3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVux5qCK|ryP M17DXlch\A>? Mlqy[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 MUeyN|A{QDJ5Mx?=
ALL-SIL NHPy[GNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\4TVYy6oDLzszN Ml7PO{Bl Mkjk[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 Mn\MNlMxOzh{N{O=
KE37 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYCx5qCK|ryP NVK4UZZmPyCm NEHaWJll\WO{ZXHz[ZMhfGinIHPlcIwhdnWvYnXyJJNq\26rZnnjZY51dHl? MXKyN|A{QDJ5Mx?=
Karpas-45 NV\uOms1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlv5NgKBkc7:TR?= NXjMVHJ1PyCm MVfk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> M3LkNVI{ODN6Mkez
RPMI-8402 MnG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV63Ooc4OeLCid88US=> MVW3JIQ> MU\k[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> MXKyN|A{QDJ5Mx?=
Jurkat MmHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7FZYpSOeLCid88US=> NIT2fJM4KGR? Mlu5[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 NYizeWs2OjNyM{iyO|M>
MOLT-4 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PySlHjiIoQvF2= Mn;xO{Bl NFHnZ3Rl\WO{ZXHz[ZMhfGinIHPlcIwhdnWvYnXyJJNq\26rZnnjZY51dHl? NHHOTlIzOzB|OEK3Ny=>
PF-382 M{XXXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXGd|FbOeLCid88US=> MljDO{Bl MnLn[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 MknUNlMxOzh{N{O=
CCRF-CEM NU\ZUZhnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYix5qCK|ryP NID5WpQ4KGR? NELuR3Fl\WO{ZXHz[ZMhfGinIHPlcIwhdnWvYnXyJJNq\26rZnnjZY51dHl? Ml3ENlMxOzh{N{O=
LOUCY NUPaWY1CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPY[Xgy6oDLzszN MlvTO{Bl MmC3[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 NX\YcJBNOjNyM{iyO|M>
MOLT-16 NULrU45lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXX6bFBWOeLCid88US=> Mo[5O{Bl NGfZUIRl\WO{ZXHz[ZMhfGinIHPlcIwhdnWvYnXyJJNq\26rZnnjZY51dHl? MXSyN|A{QDJ5Mx?=
MM1S NVq3SVBrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXsUHJ{OC1{IN88US=> MlHYNlQhcA>? MkDwTWM2OD1yLkWg{txO NWHmTZRtOjJ6MkmyN|Q>
NCI-H929 NH3EUVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XvdFAuOiEQvF2= NEe4V4UzPCCq MnvZTWM2OD1yLkK1JO69VQ>? MkTONlI5Ojl{M{S=
KMS12-BM  MnT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2L5blAuOiEQvF2= NHX1NG8zPCCq NU[zeoVUUUN3MP-8olIh|ryP MXuyNlgzQTJ|NB?=
MDA-MB-436 MVPGeY5kfGmxbjDBd5NigQ>? NITPRnUyKM7:TR?= NWW1VlhPOjRiaB?= NVrhdFJOemWmdXPld{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFHLWC=> MnTzNlI1QDh3OUC=
SUM149PT NWHIXm1CTnWwY4Tpc44hSXO|YYm= NWjkSVdtOSEQvF2= M3zzWVI1KGh? NVL6[|FkemWmdXPld{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFHLWC=> NXLpSGRtOjJ2OEi1PVA>
SUM1315MO2 MVnGeY5kfGmxbjDBd5NigQ>? MlPoNUDPxE1? M1i5cVI1KGh? NGfpO|Bz\WS3Y3XzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiQVvU Ml\nNlI1QDh3OUC=
HCC1937 M2TtVmZ2dmO2aX;uJGF{e2G7 NYnCN2NJOSEQvF2= NX\lXm8zOjRiaB?= NX3hNWFtemWmdXPld{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFHLWC=> M174d|IzPDh6NUmw
HCC827 Mkf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;Re2YxNTNizszN NV;rPHRJPzJiaB?= NXvEfol2UUN3ME2wMlMh|ryP NVzifldtOjF{MkC0O|Q>
PC-9  MmK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4myRlAuOyEQvF2= NVzUbpRkPzJiaB?= NE[1dJdKSzVyPUCuPEDPxE1? M3nDb|IyOjJyNEe0
LN229 NHrBU3dHfW6ldHnvckBCe3OjeR?= NHfCSHUyKM7:TR?= NVzxPG5uPDhiaB?= MnTBbY5lfWOnczDheZRweGijZ3;zc41mKG[xcn3heIlwdg>? MkXoNlExPjJ7OUO=
U87 NWHBOIxiTnWwY4Tpc44hSXO|YYm= NHvqT|EyKM7:TR?= Mk\rOFghcA>? MYDpcoR2[2W|IHH1eI9xcGGpb4PvcYUh\m:{bXH0bY9v NHjv[WkzOTB4Mkm5Ny=>
U373 NIqyZY1HfW6ldHnvckBCe3OjeR?= NW\CT2VsOSEQvF2= NGP0cnA1QCCq M3rvZolv\HWlZYOgZZV1d3CqYXfvd49u\SCob4LtZZRqd25? NHTIN4wzOTB4Mkm5Ny=>
SF767 MnH1SpVv[3Srb36gRZN{[Xl? M4XGclEh|ryP NFP4NpU1QCCq NWPhb4N6cW6mdXPld{BifXSxcHjh[49{d22nIH\vdo1ifGmxbh?= M2TMOVIyODZ{OUmz
Mel-Juso MWXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M3zDflAvODIkgKOxNQKBkc7:TR?= NX3xfFVmPzJiaB?= NHPWfmlqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 MofvNlExPDh5OEW=
518A2  NIrXToVE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MofYNE4xOeLCk{Gw5qCK|ryP M2rxOlczKGh? MojqbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NEfvPG4zOTB2OEe4OS=>
Mel-Juso  MYnGeY5kfGmxbjDBd5NigQ>? MnHONE4xODIkgKOx5qCK|ryP MoLRNlQhcA>? Mnu4d5VxeHKnc4Pld{BxcG:|cHjvdplt[XSrb36gc4YheGixc4DoZZRq\HmuIHnuc5NqfG:uIEOtb4lv[XOnIHTve45{fHKnYX2geIFz\2W2cx?= M{LEeFIyODR6N{i1
518A2 Mm[5SpVv[3Srb36gRZN{[Xl? NXvtWnNsOC5yMEJihLMy6oDLzszN MWGyOEBp M1G3O5N2eHC{ZYPz[ZMheGixc4Doc5J6dGG2aX;uJI9nKHCqb4PwbIF1cWS7bDDpco9{cXSxbDCzMYtqdmG|ZTDkc5dve3S{ZXHtJJRiemendIO= NGHQdHYzOTB2OEe4OS=>
PC3  MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfiNlRp MkDrS2k2OMLiPTCxNFAhdk1? NF36ZVAzODV3MUC2NS=>
U87MG NHTVSJlHfW6ldHnvckBCe3OjeR?= NIjTU3gxNjFvMTFOwG0> NGC4SGozPOLCiXlCpC=> M2XLXWROW09? NVj3S3JRcW6qaXLpeJMhWEl|Sz3t[YRq[XSnZDDzbYdv[Wyrbne= M4DiTlE6PjN|Nkiz
U138MG MXfGeY5kfGmxbjDBd5NigQ>? Mnf0NE4yNTFizszN Mn3lNlTjiImqwrC= NWe1OnVLTE2VTx?= MlPKbY5pcWKrdIOgVGk{Uy2vZXTpZZRm\CC|aXfuZYxqdmd? MVmxPVY{OzZ6Mx?=
U118MG M3XvO2Z2dmO2aX;uJGF{e2G7 MV2wMlEuOSEQvF2= NXnYbnpxOjUkgJnoxsA> NXnY[HRLTE2VTx?= NFrQdnlqdmirYnn0d{BRUTONLX3l[IlifGWmIIPp[45idGmwZx?= NIOzPWYyQTZ|M{[4Ny=>
U87MG M2fPOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInaWndKSzVyPUCuNVQh|ryP MlvGNVk2QDR{Mke=
IGROV-1 NWr3WYNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLDTWM2OD1yLkC2JO69VQ>? M1vqUVE6PTh2MkK3
DETROIT562 NWrFWHJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELHSXhKSzVyPUCuNVMh|ryP NXewRpVCOTl3OESyNlc>
PC3  NWCwOHNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfaV2xKSzVyPUCuNVAh|ryP NVK3NJZNOTl3OESyNlc>
SKOV-3 MmXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFizOW5KSzVyPUCuNVIh|ryP MVuxPVU5PDJ{Nx?=
HUVEC M2myb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zGSmlEPTB;MD6wPEDPxE1? MYWxPVU5PDJ{Nx?=
UCH-1  NFK1SoJHfW6ldHnvckBCe3OjeR?= M1;NUVAuPSEQvF2= MoXubY5pcWKrdIOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCkb4ToJGFMXCCjbnSgcXRQWiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NX\ZbGpNOTl3Mki0OFE>
UCH-1  NHrmdo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVu0cpVtOC5yMT2xNEDPxE1? NFW3UWs3KGR? MV\pcohq[mm2czDwdo9tcW[ncnH0bY9vKGSxc3Wg[IVx\W6mZX70cJk> NGDoS5AyQTV{OES0NS=>
UCH-1  MXXBdI9xfG:|aYOgRZN{[Xl? NUTIOHBkOC5zLUGwJO69VQ>? MUiyOEBp M{nMO2ROW09? NFTxb5RqdmS3Y3XzJIFxd3C2b4Ppdy=> NV\Vd3Y4OTl3Mki0OFE>

... Click to View More Cell Line Experimental Data

In vivo試験 When tumors reach 50-100 mm3, animals are randomized and treated with vehicle or PI-103. PI-103 exhibits significant activity, decreasing average tumor size by 4-fold after 18 days. [2] Mice treated with PI-103 have no obvious signs of toxicity premorbidly (based on body weight, food and water intake, activity, and general exam) or at necropsy. Treated tumors display decreased levels of phosphorylated Akt and S6, consistent with blockade of p110α and mTOR. PI-103 treatment is cytostatic to glioma xenografts. [2]
臨床試験
特集 The first potent, synthetic mTOR inhibitor.

プロトコル (参考用のみ)

キナーゼアッセイ: [3]

Enzyme Assays Phosphatidylinositide 3-kinase inhibitory activity was determined using a scintillation proximity assay in the presence of 1 μmol/L ATP. Inhibition of mTOR protein kinase was determined using a TR-FRET-based LanthaScreen method from Invitrogen. Compounds were assayed at a maximum concentration of 10 μmol/L in the presence of 1 μmol/L ATP, and IC50 values were determined using GraphPad Prism software.

細胞アッセイ: [2]

細胞株 U87MG cells
濃度 0.5 μM
反応時間 24 hours
実験の流れ U87MG cells are treated with PI-103 for 24 hours. Cell death is quantified by colorimetric determination of LDH activity using a cytotoxicity detection kit. Percentage of cell death (mean of three 12-well plates per experimental point) is calculated [(experimental value- low control)/(high control -low control) × 100], where the low-control cells are DMSO treated and high-control cells are Triton treated (1% Triton X-100, 30 min, 37 °

動物実験: [2]

動物モデル 6- to 12-week-old Balbc nu/nu mice bearing U87MG:ΔEGFR cells
製剤 50% DMSO
投薬量 5 mg/kg
投与方法 Administered via i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download PI-103 SDF
分子量 348.36
化学式

C19H16N4O3

CAS No. 371935-74-9
保管 2年-20℃
6月-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 24 mg/mL (68.89 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
In vivo 1% DMSO+30% polyethylene glycol+1% Tween 80 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 Phenol, 3-[4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]-

カスタマーフィードバック (4)


Click to enlarge
Rating
Source Mol Carcinog, 2012, 52, 667-75 . PI-103 purchased from Selleck
Method Western blot
Cell Lines MCF7 cells
Concentrations 0-1 μM
Incubation Time 24 h
Results In BRCA1-KD MCF7 cells, treatment of PI-103, a PI3K/mTOR inhibitor, abolished phosphorylation of AKT and its substrate GSK3b, in a dose dependent manner (Figure A). Treatment of PI-103 reduced the phosphorylation of AKT in all BRCA1 mutant breast cancer cells tested (Figure B). Phosphorylations of downstream targets of AKT, such as phospho-GSK3b (S9) and phospho-BAD(S112) were also reduced by PI-103 treatment. Phosphorylation of mTOR at S2448, which is also known to be phosphorylated by AKT, was also reduced by PI-103 resulting in reduced phosphorylation of S6 ribosomal protein at S235/236 (Figure B). The effect of PI-103 was much more potent than LY294002 in MDA-MB-436 cells (Figure B)

Click to enlarge
Rating
Source Mol Carcinog, 2012, ahead of print. PI-103 purchased from Selleck
Method MTT assay
Cell Lines MCF7 cells
Concentrations 0.01-1 μM
Incubation Time 48 h
Results Knockdown of BRCA1 can sensitize the MCF7 cells to Perifosine in a dose-dependent manner (Figure A). BRCA1-KD also sensitizes the MCF7 cells to dual PI3K/mTOR inhibitors, such as PI-103 or BEZ235 (Figure B, D). Another inhibitor, PIK-75 which specifically inhibits PI3Ka and PI3Kg, but not mTOR, also showed similar effects on proliferation of BRCA1-KD MCF7 cells (Figure C).

Click to enlarge
Rating
Source Dr. Zhang of Tianjin Medical University. PI-103 purchased from Selleck
Method Western blot
Cell Lines Breast cancer cells
Concentrations 0-1 nM
Incubation Time 24 h
Results PI-103 treatment resulted in a reduction of Akt phosphorylation in Breast cancer cells.

Click to enlarge
Rating
Source Saraswati Sukumar of Johns Hopkins University School of Medicine, PI-103 purchased from Selleck
Method Western blot
Cell Lines T47D cells
Concentrations
Incubation Time 1 h
Results PI-103 treatment resulted in a reduction of Akt phosphorylation in T47D cells.

文献中の引用 (21)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related PI3K 阻害剤

  • GDC-0032

    GDC-0032 is a potent, next-generation PI3K inhibitor targeting PI3K alpha.

    Features:A beta isoform-sparing PI3K inhibitor.

  • Pilaralisib (XL147)

    Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.

  • GNE-317

    GNE-317 is a potent, brain-penetrant PI3K inhibitor.

  • PI-3065

    PI-3065 is a selective p110δ inhibitor with IC50 of 15 nM, >70-fold selectivity over other PI3K family members.

  • LY294002

    LY294002は、p110α、p110δとp110βのPI3K阻害剤で、IC50 がそれぞれ 0.5 μM、0.57 μM、0.97 μMです。

  • 3-Methyladenine (3-MA)

    3-Methyladenine (3-MA) は選択の自噬とリン酸イノシトール3キナーゼ(キナーゼ)阻害剤、Vps34 と PI3Kγ に作用する時、 IC50 がそれぞれ 25 nM と 60 nM になる。自動食物胞の形成を妨害すること。

  • CAL-101 (Idelalisib, GS-1101)

    CAL-101 (Idelalisib, GS-1101)は、2.5nMのIC50によるp110δの選択的なPI3KクラスI阻害剤です。

  • Wortmannin

    ワートマニンはミオシン軽鎖キナーゼ(MLCK)のマルチターゲットの阻害剤、IC50がぞれぞれ0.17μMと3nMになる。自動食物胞の形成を妨害すること。

  • BEZ235 (NVP-BEZ235, Dactolisib)

    BEZ235 (NVP-BEZ235, Dactolisib)は競争性的なPI3K、mTOR 阻害剤、 p110α, p110γ, p110δ と p110β を作用すると、 IC50 がぞれぞれ 4 nM, 5 nM, 7 nM と 75 nMになる.

  • BKM120 (NVP-BKM120, Buparlisib)

    BKM120 (NVP-BKM120, Buparlisib)は、p110α、p110β、p110δとp110γの選択的なPI3K阻害剤で、IC50 がそれぞれ 52-99 nM、166 nM、 116 nM、 262 nMです。

最近チェックしたアイテム

Tags: PI-103を買う | PI-103供給者 | PI-103を購入する | PI-103費用 | PI-103生産者 | オーダーPI-103 | PI-103代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ